Research programme: dyslipidaemia therapies - Mazal Plant Pharmaceuticals

Drug Profile

Research programme: dyslipidaemia therapies - Mazal Plant Pharmaceuticals

Alternative Names: MAHDL-01

Latest Information Update: 20 Mar 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mazal Plant Pharmaceuticals
  • Class Antihyperlipidaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Hypercholesterolaemia

Highest Development Phases

  • Preclinical Hypercholesterolaemia; Hypoalphalipoproteinaemia

Most Recent Events

  • 20 Mar 2012 MAHDL 01 is still in preclinical development for Hypercholesterolaemia and Hypoalphalipoproteinaemia in USA
  • 31 Mar 2011 MAHDL 01 is available for licensing in USA as of 31 Mar 2011. http://mazalpharmaceutical.com
  • 19 Feb 2010 Preclinical trials in Hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top